Assessment of sun-safety education behavior via spectrophotometric evaluation: A preliminary study.

Background: Biases inherent in self-assessment of sun exposure and sun-safe behavior may lead to inaccurate conclusions about the effectiveness of sun-safety educational programs.

Objectives: We aimed to compare self-reports to objective measures of sun exposure, when examining the effectiveness of passive versus active educational interventions.

Methods: From May to June 2018, 73 participants recruited at a dermatology clinic were sequentially assigned to receive sun-safety education through one of 3 modes: interactive online module, video, or no education.

Fact or Fiction? Adipose-Derived Stem Cells and Platelet-Rich Plasma for the Treatment of Vulvar Lichen Sclerosus.

Objective: The aim of the study was to summarize and review the evidence for the efficacy and safety of adipose-derived stem cells (ADSCs) and platelet-rich plasma (PRP) for the treatment of vulvar lichen sclerosus (LS).

Materials And Methods: PubMed/MEDLINE, Ovid, Web of Science, and clinicaltrials.gov were searched from inception up to May 7, 2018.

The Burden of Moderate to Severe Atopic Dermatitis in Canadian Children: A Cross-Sectional Survey.

Objectives: Although atopic dermatitis (AD) has significant impacts on quality of life, data from Canada on the subject are limited. This survey aims to assess the burden of moderate to severe AD on quality of life and disease management for pediatric patients and their caregivers in Canada.

Methods: The Eczema Society of Canada conducted an online national cross-sectional survey in English and French.

Dupilumab: an evidence-based review of its potential in the treatment of atopic dermatitis.

Introduction: Atopic dermatitis (AD) is a recurrent, pruritic inflammatory skin disease with complex immunopathogenesis characterized by a dominant T2 response. Dupilumab is an interleukin (IL)-4 receptor alpha antagonist that subsequently blocks IL-4 and IL-13 signaling. It has recently been approved for the treatment of adult patients with moderate-to-severe AD whose current treatment options are limited.

Dupilumab: A review of its use in the treatment of atopic dermatitis.

Atopic dermatitis (AD) is a chronic, pruritic immune-mediated inflammatory dermatosis characterized by a T helper 2 (Th2) immune response phenotype and may be associated with systemic inflammation. Dupilumab is an interleukin 4 (IL-4) receptor α-antagonist that inhibits IL-4 and IL-13 signaling through blockade of the shared IL-4α subunit. Blockade of IL-4/13 is effective in reducing Th2 response.